source
- Biopharma dealmaking in 2026: The recovery gathers speed in Q2It’s always darkest before the biotech dawn, and at no time was that more true than last summer, as biotech was experiencing a crisis of confidence. We tracked an industry-wide downturn in expectat…Endpoints · 7d ago↗ source
- Vertex was only bidder for Crinetics in year's second-highest M&A premiumTo gain control of Crinetics Pharmaceuticals, Vertex Pharmaceuticals was willing to pay the second-highest premium so far in biopharma's banner year for M&A. And the Boston drugmaker was bidding ag…Endpoints · 7d ago↗ source
- From Big Pharma to specialty: why moving closer to the patient changes everythingWorking at a Big Pharma has its benefits, but there are limitations too. SERB Pharmaceuticals’ Thomas Kolaras discusses how moving to a midsize company creates new opportunities for sharpened think…